The initial plan for using and disseminating knowledge (Work Package 7, Deliverable 1) is detailed below. It includes dissemination strategies, target groups and the strategic impact of the project in terms of improvement of competitiveness and creation of market opportunities for the participants.
| Consortium partners |
Bi-annual meetings of CLINT Steering Committee and circulation of minute
Conference calls of project partners and production of project update reports/internal assessments (as requested by the Co-ordinator) |
| Transplant community (physicians, statisticians, scientists, nurses and data managers) |
Project updates in newsletters and on website of project partners (EBMT/ CIBMTR)
Information sessions and relevant workshop sessions at EBMT annual meetings
Written communications to members of EBMT and CIBMTR drawing attention to the launch of the CLINT website and ongoing updates on the information added to the website
Links established between CLINT and the Clinical Trials sections of the EBMT and CIBMTR websites
Appropriate access-rights given to relevant users of the CLINT portal for exchange of data, trial design and modelling and statistical methods
Access to study protocols made available to EBMT member centres |
| National societies |
Annual update to Heads of National Societies to inform them of the project
Appropriate access-rights given to relevant users of the CLINT portal for exchange of data, trial design and modelling and statistical methods |
| Other physician groups |
Establishment of links with other professional societies from other disciplines interested in the application of HSC transplantation
Project reports distributed to these organisations |
| Donors and donor groups |
Annual meetings with the World Marrow Donor Registries (WMDA) and heads of Donor registries.
Links between CLINT and WMDA website and provision of project updates
Links between CLINT and websites of Donor Registries
Project reports distributed to these organisations
Appropriate access-rights given to relevant users of the CLINT portal for exchange of data, trial design and modelling and statistical methods |
| Patient and patient groups |
Establish links with relevant patient groups and provide regular project updates
Project reports distributed to these organisations
Provide access to information on Informed Consent and Data Protection arising from the project |
| Health authorities |
Reports arising from the ethics work package will be shared with contacts in health authorities across Europe |
| Pharmaceutical and biotechnology industries |
Formation of an Industry Advisory Committee. Minutes of meetings circulated to participating companies
General project information updates at the annual Industry meeting held with Corporate Patrons of the EBMT at annual meetings
Project reports distributed to EBMT Corporate Patrons |
| Public |
Project presentation and relevant deliverables to be made publicly available on CLINT website |
|
The infrastructure under development will enable the EBMT to act as ‘Sponsor’ of multi-centre academic clinical trials. This is a specialisation that the EBMT will be able to offer to National Societies for the conduct of national level studies.
The EBMT will benefit from the previous experience and work of CIBMTR in this area, allowing European study groups to remain competitive with groups in the U.S. It is also an opportunity to improve global research infrastructures in the field of SCT.
The strengthening of the clinical trials infrastructure will attract Industry funding for EBMT sponsored trials and thereby allow further growth and development of this infrastructure, which in turn will facilitate future academic led trials.
Overcoming legal and ethical issues related to multi-national clinical trials will facilitate future research
Publicity around the ethical issues relating to the participation of donors and patients in clinical trials (Informed Consent and Data Protection) should serve to reassure the public with regard to the conduct and participation in clinical trials. |